Health Care • Biotechnology: Pharmaceutical Preparations
$1.66 ▲ +0.04
(+2.47%)
MKT CAP: $1.24B • VOL: 1.98M
52W L $1 52W H $2
OPK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $606.9M | $713.1M | $863.5M |
| YoY Revenue Growth % | -14.9% | -17.4% | — |
| Gross Profit | $205.9M | $218.5M | — |
| Gross Margin % | 33.9% | 30.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$117.4M | -$152.1M | -$157.0M |
| Operating Margin % | -19.3% | -21.3% | -18.2% |
| Net Income (GAAP) | -$225.68B | -$53.22B | -$188.86B |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$178.5M | -$183.5M | -$28.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$178.5M | -$183.5M | -$28.2M |
| FCF Margin % | -29.4% | -25.7% | -3.3% |
| Return on Invested Capital (ROIC %) | -10.2% | -12.8% | — |
| Cash & Short-Term Equivalents | $364.4M | $426.6M | — |
| Total Debt (Short + Long Term) | $2.3M | $3.0M | — |
| Total Stockholders' Equity | $1.27B | $1.37B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OPK.